🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Grateful for presentations from these incredible #SDS experts at Camp Sunshine! 🧬🔬 Thank you all!

We welcome Dr. Christopher Reilly, Dana-Farber Cancer Institute, to Team Telomere's Board of Medical Advisors! His clinical-translational research & Hematology/Oncology expertise will add to our team and expand efforts to serve adults with TBDs. Read more: bit.ly/MABtt

Join our TBD patient registry! You can shape research and pave the way for treatments. We currently have 65 community members in our registry - help us reach 100 participants in the next two months! Let's accelerate progress together! Learn more: rare-x.org/tbd-dc/

🌟Exciting News!🌟 We're thrilled to announce the first cohort of Team Telomere’s Centers of Excellence for Telomere Biology Disorders! These centers are dedicated to advancing care, support, advocacy, education, and research for TBDs. Learn more: teamtelomere.org/centers-of-exc…

Join us for our next Community Chat on Hematology in #Telomere Biology Disorders (#TBD) with Dr. Chris Reilly from Dana-Farber Cancer Institute! Open to all individuals impacted by a TBD, family, and other community members. Register here: us02web.zoom.us/meeting/regist…

Today, #TeamTelomere hosted our first TRACTS Roundtable! The roundtable was focused on Clonal Hematopoiesis in TBDs – with the goals of advancing research, inspiring progress, and improving care. Thank you to all our speakers and attendees! Stay tuned for updates! #TBDawareness

A nice commentary in this issue of Blood Journal for our paper looking at the role of #ClonalHematopoiesis in #TBD from Chris Reilly and Mikko Myllymäki - a somatic symphony; telomeres and CH! ashpublications.org/blood/article/… Fernanda Gutierrez-Rodrigues Sharon A. Savage, M.D. ashpublications.org/blood/article/…

CONGRESS | #ASH24 | PRESENTATION Shai Shimony Dana-Farber highlights results from a post hoc analysis of the phase III CPX-351-301 trial. Results suggest that the benefit of CPX-351 vs 7+3 chemotherapy is driven by the presence of AML-MR defining mutations. Follow our live feed

We’re thrilled to be at #ASH2024, representing the Telomere Biology Disorder community! 🎉 Visit us at Booth 6! Stop by to connect, grab some TBD resources, and treat yourself to telomere goodies and York Peppermint Patties ASH #TBD #TeamTelomere